Synthetic Biology Market Size, Share, and Trends 2026 to 2035

Synthetic Biology Market Size and Forecast 2026 to 2035

The global synthetic biology market size was estimated at USD 24.58 billion in 2025 and is predicted to increase from USD 30.29 billion in 2026 to approximately USD 252.42 billion by 2035, expanding at a CAGR of 26.23% from 2026 to 2035. The market growth is driven by the rising demand for bio-based, sustainable, and advanced DNA sequencing and synthesis technologies.

Synthetic Biology Market Key Takeaways

• North America dominated the market with the largest market share of 39.4% in 2025.
• Asia Pacific is expected to be the fastest-growing during the forecast period.
• By technology, the PCR sector held the biggest market share at 28% in 2025.
• By product, the oligonucleotide/oligo pools & synthetic DNA segment has accounted market share of 35.9% in 2025.
• By application, the healthcare sector leads the market and accounted market share of around 57% in 2025.
• By end-use, the pharmaceutical and biotech companies' group had the highest revenue share of 52.3% in 2025.

Synthetic Biology Market Overview

Synthetic biology is a field of study that combines multiple areas, including molecular biology, biophysics, biotechnology, and genetic engineering. The market includes synthetic DNA and RNA, enzymes such as polymerase and ligases, and advanced CRISPR genome-editing tools. The industries increasingly use engineered biological systems to develop innovative solutions in healthcare, agriculture, industrial biotechnology, food production, and sustainable manufacturing. The continuous technological innovation in synthetic biology through drug discovery and genome engineering is driving the expansion of the market. The significant investments from biotechnology firms, pharmaceutical companies, and governments are further supporting market expansion.

Synthetic Biology Market Growth Factors

• The global synthetic biology market is growing due to increased research and development in gene editing, DNA synthesis, and genome engineering technologies.
• The growing demand for sustainable alternatives encourages the use of synthetic biology for producing biofuels, biodegradable materials and manufacturing environmentally friendly solutions.
• The government and private sector are supporting synthetic biology by increasing R&D funding in drug discovery and the development of DNA sequencing and synthesis. The increasing collaborations with research institutes and large organizations support innovation and expand research capabilities.

How is AI Impacting the Synthetic Biology Market?

Artificial intelligence is transforming the synthetic biology market. Artificial intelligence is being used to design genetic sequences, predict protein structures, and accelerate the development of products with higher speed and accuracy than traditional lab systems. Integration of AI reduces trial and error in experiments and shortens development timelines significantly. Machine learning models analyze massive datasets of genetic sequences, protein structures, and CRISPR tools to rapidly resolve unique problems and also help identify optimal gene combinations for therapies.

Market Scope

Market Dynamics

Drivers

Increasing synthetic vaccinations and medications

The market will likely develop in response to the rising demand for protein treatments, individualized medicine, and studies into synthetic drugs and vaccines. During the forecast period, the growth of the synthetic biology market is predicted to be accelerated by other variables such as increasing artificial biology applications, more excellent synthetic biology investment, decreased synthesizing prices and DNA sequencing, and increased R&D spending and activities.

Improvements in diagnosis and treatment

Synthetic biology is employed in the healthcare business because it can improve diagnosis and therapy options for a wide range of disorders by targeting precisely the site of the disease and causing no side effects. Furthermore, the use of genetically modified viruses to repair damaged genes in individuals with inherited illnesses like severe combined immune deficiency (SCID) or epidermolysis bullosa has skyrocketed.

Aside from that, technology for carrying out synthetic biology has grown more accessible, and internet use has enabled the free exchange of ideas and information, supporting market growth. Furthermore, considerable expansion in the healthcare industry and a rise in the number of research units of synthetic biology globally are favorably influencing the market.

Restraints

Concerns about ethics and biosafety

The primary biosafety risk in synthetic biology is the unintentional or planned introduction of synthetic organisms to the environment for research or other reasons. When synthetic microorganisms are put into the atmosphere, they can mutate or interact with existing species, resulting in crossbreeding and bio errors. These consequences may endanger the habitats of wild animals. Furthermore, the rise of antibiotic-resistant superbugs poses a significant biosecurity danger. In recent years, the European Union (EU) has funded several studies on the environmental effects of genetically modified bacteria released for bioremediation or plant growth. These limitations could hamper market expansion in the coming years.

Opportunities

Rising funding for research and development

The rising spending, booming investments and funding for research and development activities in the market are observed to offer a plethora of opportunities for the market's growth. To find new treatments, pharmaceutical companies have gotten more significant funding for research and development. The government has taken initiatives to subsidize various biotech and pharmaceutical businesses to improve the pharmaceutical industry and increase global competitiveness. As a result, funding and investment in R&D have increased over time. Pharmaceutical and biotechnology companies invest a lot of money in research to develop revolutionary drugs that may treat new diseases and meet the growing demands of the healthcare sector.

Segments Analysis

Technology Insights

Why Did the Polymerase Chain Reaction (PCR) Segment Dominate the Synthetic Biology Market?

The polymerase chain reaction (PCR) segment registered its dominance in the global market in 2025 due to its accuracy, speed, and cost-effectiveness. The polymerase chain reaction has extensive applications in areas such as DNA cloning, gene assembly, forensic research, and genomics. Continuous improvement in real-time PCR systems and high throughput is increasing efficiency, leading to the acceleration of the development of new therapeutic candidates.

The genome editing segment is expected to grow at the fastest CAGR in the synthetic biology market over the forecast period due to its role in gene editing, genome sequencing, and cellular engineering. The gene editing techniques have the capability to develop products with specific traits that have transformed the human and animal healthcare sectors. The advancement in CRISPR-based tools and computational biology has improved precision and scalability, which contributes to the market growth of the segment.

Global Synthetic Biology Market Revenue, By Technology, 2022-2024 (US$ Bn)

Product Insights

What Made Oligonucleotides the Leading Segment in the Synthetic Biology Market?

The oligonucleotide segment led the market with the largest share in 2025. This is mainly due to their key role as building blocks for gene synthesis, genome editing, and synthetic biology research. The growing demand for custom DNA and RNA sequences in therapeutic development and biotechnology research continues to drive segmental growth.

The enzymes segment is expected to witness the fastest growth in the upcoming period. This is because enzymes play a vital role in synthetic biology, including DNA manipulation, amplification, assembly, and protein engineering. Enzymes such as polymerases, ligases, nucleases, and restriction enzymes are widely used in research and commercial applications in synthetic biology.

Global Synthetic Biology Market Revenue, By Product, 2022-2024 (US$ Bn)

Application Insights

Why Did the Healthcare Segment Hold the Largest Share of the Synthetic Biology Market?

The healthcare segment held a dominant position in the market with the largest share in 2025, driven by growing demand for advanced therapeutics, vaccines and gene therapies. Strong esearch and development investments, strategic collaborations, and increasing adoption of advanced cell and gene therapies are supporting the market expansion.

The non-healthcare segment is expected to expand rapidly in the market with a CAGR in the coming years. The growth is supported by the use of synthetic biology in agriculture, food production, environmental management, and industrial biotechnology. Innovation in synthetic biology allows the development of sustainable bioplastic and crop enhancement solutions, which further contribute to the market growth of the segment.

Global Synthetic Biology Market Revenue, By Application, 2022-2024 (US$ Bn)

End-User Insights

The Pharmaceutical and Biotechnology Companies Segment Dominated the Synthetic Biology Market?

The pharmaceutical and biotechnology companies segment led the global market in 2025, driven by their central role in the advancement of therapeutic solutions. The increasing investment in drug discovery, biologics development, gene therapies, and vaccine research in pharmaceutical and biotechnology companies is driving the growth of the segment in the market.

The academic and government research institutes segment is expected to witness the fastest growth in the market over the forecast period. The segment contributes to the market by fundamental research, technology development, and scientific collaborations. The institutes play a critical role in expanding scientific knowledge and training skilled professionals.

Global Synthetic Biology Market Revenue, By End-User, 2022-2024 (US$ Bn)

U.S. Synthetic Biology Market Size and Growth 2026 to 2035

The U.S. synthetic biology market size reached USD 7.14 billion in 2025 and is predicted to be worth around USD 69.1 billion by 2035, growing at a CAGR of 25.48% between 2026 and 2035.

What Factors Made North America the Dominant Region in the Market?

North America dominated the synthetic biology market with the largest share in 2025, driven by the strong biotechnology ecosystem and advanced research infrastructure. The region benefits from the presence of leading biotechnology companies, pharmaceutical manufacturers, and research institutions. The growing investment from the public and private sectors, including funding from government initiatives, is further driving the growth of the market.

U.S. Market Trends

The U.S. represents the largest market for synthetic biology. The growth of the market in the U.S. is driven by the strong presence of key market players. The increasing research in gene editing and synthetic genomes is creating significant opportunities across the United States. The country has a robust regulatory environments encourages biotechnological advancement and strong adoption of advanced therapies.

Which Factors Made Europe a Significantly Growing Region in the Market?

Europe is expected to grow at a significant CAGR in the upcoming period. The growth is supported by robust research programs, favorable regulatory frameworks for biotechnology innovation, and increasing sustainability initiatives. The region is experiencing growing demand for bio-based chemicals, advanced therapeutics, and agricultural biotechnology solutions. The increasing public funding and investment from the government are promoting research and innovation in the synthetic biology field, which supports the expansion of the market in the region.

Germany Market Trends

Germany leads the European synthetic biology market through its strong industrial biotechnology sector, advanced manufacturing capabilities, and extensive research network. The country benefits from significant investments in biotechnology, including genetic engineering, sustainable production technologies, and advanced research infrastructure. The ongoing technological innovation in therapies is also fueling the demand for synthetic biology products across various biological applications

What Makes Asia-Pacific the Fastest-Growing Region in the Market?

Asia Pacific is expected to grow at the fastest CAGR in the synthetic biology market during the forecast period. The growth is driven by expanding biotechnology industries, rising healthcare expenditure, and increasing government support for research. Countries such as China, India, Japan, and South Korea are investing in genomic technologies, agricultural biotechnology, and pharmaceutical innovations. The rising demand for advanced healthcare solutions, biologic therapies, and sustainable manufacturing across the region is supporting the market growth.

China Market Trends

China is the fastest-growing country within the Asia Pacific synthetic biology market. The growth is driven by strong government funding, expanding biotechnology infrastructure, and increasing investments in genomics, healthcare, and industrial biotechnology. The country is rapidly strengthening its research capabilities and commercial production capacity to expand the domestic pharmaceutical industry. The rising need for effective therapies is expected to enhance the growth of the market across the country.

Why is the Synthetic Biology Market Growing in Latin America?

The synthetic biology market in Latin America is growing due to increasing investments in biotechnology research, rising adoption of bio-based solutions in agriculture and healthcare, and supportive government initiatives promoting innovation. Countries such as Brazil and

Argentina are focusing on improving agricultural productivity through engineered crops and biofertilizers, which is accelerating demand. In addition, expanding pharmaceutical manufacturing and growing awareness of sustainable and cost-effective biological solutions are further supporting market growth in the region.

What Drives the Market in the Middle East & Africa?

The synthetic biology market in the Middle East & Africa (MEA) is driven by rising investments in healthcare innovation, increasing focus on food security, and growing adoption of biotechnology in agriculture and industrial applications. Governments in the region are actively supporting diversification away from oil-based economies, encouraging research in life sciences and biotechnology. Additionally, increasing demand for advanced medical solutions, bio-based chemicals, and sustainable agricultural practices is further propelling market expansion across MEA countries.

Competitive Landscape

The synthetic biology market is highly competitive and characterized by major pharmaceutical and biotechnology companies focused on leveraging R & D capabilities, technological advancement, and expanding their portfolio to maintain market presence. The companies are expanding capabilities in gene synthesis, genome engineering, DNA sequencing, and bio-based manufacturing solutions. Collaboration between pharmaceutical companies, academic institutions, and synthetic biology firms is accelerating product development. The key market companies are focusing on strategic collaboration and partnerships to deliver diversified applications, supporting their market position and growth. Ginkgo Bioworks and NOVUS International partnered to develop advanced feed additives to meet the changing animal agriculture industry.

To maintain a strong position in the future, key players should focus on developing next-generation biomanufacturing and leveraging scalability in DNA synthesis and genome editing. The integration of artificial intelligence and machine learning into biological design will support faster discovery, better accuracy, and reduced developmental timelines. Companies are also expected to strengthen intellectual property portfolios while building strategic collaborations with other organizations.

Synthetic Biology Market Companies

• Codexis, Inc.
• Bota Biosciences Inc.
• Creative Enzymes.
• Creative Biogene.
• Illumina, Inc.
• Enbiotix, Inc.
• New England Biolabs
• Merck Kgaa (Sigma-Aldrich Co. Llc)
• Novozymes
• Euro fins Scientific
• Scarab Genomics, Llc
• Pareto Bio, Inc.
• Synthetic Genomics Inc.
• Synthego
• Thermo Fisher Scientific, Inc.

Recent Developments

• In February 2026, Researchers at the Massachusetts Institute of Technology (MIT) launched a new research initiative that combines synthetic biology with generative artificial intelligence (AI) to address the rising global threat of antimicrobial resistance (AMR). The program is directed by Professor James J. Collins and Jammel Research, a three-year, $3 million initiative aimed at developing programmable antimicrobials utilising AI-designed proteins delivered by engineered microbes. This method aims to address drug resistance infection more accurately.
• In May 2026, Ribbon Bio launched a synthetic MiroSynth cell-free DNA product manufactured without bacterial cloning steps and the MiroMine kit that allows customers to create synthetic DNA constructs in their own labs. These advancements highlight the goal of the company to make DNA accessible to all, shifting the synthesis of complex DNA from a centralised, limited-capacity service to a more accessible, adaptable and scalable resource for the biopharma and synthetic biology sectors.

Market Segments Covered

By Technology

• PCR Technology
• NGS Technology
• Bioprocessing Technology
• Genome Editing Technology
• Other Technologies

By Product

• Enzymes
• Oligonucleotide/Oligo Pools and Synthetic DNA
• Xeno-Nucleic Acids
• Cloning Technologies Kits
• Chassis Organism

By Application

• Healthcare
  • Non-Clinical
  • Clinical
• Non-healthcare
  • Specialty Chemicals
  • Biotech Crops
  • Bio-fuels
  • Others

By End-User

• Academic and Government Research Institutes
• Biotechnology and Pharmaceutical Companies
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa